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MK-591 acutely restores glomerular size selectivity and reduces disease (ESRD) [1]. Despite an increasing understanding
proteinuria in human glomerulonephritis. of the pathogenetic mechanisms that mediate immune
Background. Leukotrienes are 5-lipoxygenated (5-LO) me- glomerular damage, the treatment of glomerulonephritistabolites of arachidonic acid that mediate some of the glomeru-
is still unsatisfactory. The treatment of glomerulonephri-lar hemodynamic and structural changes in experimental and
tis with nonselective immunosuppression, mostly withhuman glomerulonephritis.
Methods. We conducted an open-label, pilot study of the cytotoxic agents, has yielded encouraging results in some
short-term effects of leukotriene biosynthesis inhibition using forms of glomerulonephritis such as lupus nephritis [2],
an orally active 5-LO activating protein (FLAP) antagonist but is associated with significant morbidity [2–4]. In the(MK-591) on glomerular function in patients with glomerulone-
last 10 to 15 years, there have been significant advancesphritis. Eleven adult patients (seven women, median age 38
in the understanding of the pathogenesis of glomerularyears) with glomerulonephritis (5 lupus nephritis, 2 IgA ne-
phropathy, 1 membranoproliferative, 1 membranous, 1 C1q- inflammation, mostly gathered from experimental mod-
deficiency, and 1 idiopathic crescentic) and moderate renal els [5–8]. In animals with experimentally induced glomer-
insufficiency [glomerular filtration rate (GFR) 62 6 9 ml/min/
ulonephritis, an initial deposition of immune complexes1.73 m2] were given MK-591 at a dose of 100 mg orally twice
in the glomerulus is followed by recruitment and activa-a day for four days.
Results. MK-591 reduced proteinuria (albumin and IgG ex- tion of blood polymorphonuclear leukocytes (PMNs),
cretion rates) from 3233 6 1074 to 1702 6 555 mg/min and followed by influx of lymphocytes, macrophages, and
from 196 6 78 to 148 6 55 mg/min for albumin and IgG, platelets. These in turn generate a cascade of immune
respectively (P , 0.05 for both). This was not accompanied
mediators—interleukins, prostanoids, complement, oxy-by a reduction in systemic arterial pressure, GFR, or renal
gen radicals, etc.—that promotes further cellular eventsplasma flow. By analysis of the fractional clearance of polydis-
perse dextrans, baseline proteinuria resulted from a loss of size and mediates the dysfunction and structural alterations,
selectivity with enhanced passage of large (.52 A˚) dextrans ultimately leading to a chronic stage characterized by
as compared with healthy controls. Treatment with MK-591 fibrosis and glomerular obsolescence [9].caused a selective improvement in the enhanced passage of
The leukotrienes (LTs) are 5-lipoxygenated (5-LO)large (.58 A˚) dextrans without affecting the handling of
metabolites of arachidonic acid that are produced bysmaller dextrans, indicating an improvement in glomerular size
selectivity. MK-591 was well tolerated, and no adverse effects activated leukocytes, PMNs, and macrophages. The LTs
were observed. mediate glomerular hemodynamic alterations and struc-
Conclusions. Short-term therapy with MK-591 reduces pro- tural changes in experimental glomerulonephritis [10,teinuria by restoring glomerular size selectivity and thus re-
11]. LTB4 is a potent chemoattractant for neutrophilsduces transglomerular protein trafficking. These benefits may
and induces neutrophil activation and enhanced adhe-result from glomerular leukotriene biosynthesis inhibition, but
other MK-591-specific actions cannot be excluded. siveness [12, 13]. In contrast to LTB4, the peptidyl LTs
(LTC4, LTD4, LTE4) have potent effects on glomerular
hemodynamics, increasing the efferent arteriolar tone
Glomerulonephritides are common diseases that ac- and the transglomerular capillary hydraulic pressure and
count for about 20% of the new cases of end-stage renal lowering the ultrafiltration coefficient, the latter proba-
bly mediated by mesangial cell contraction [14]. The net
result is a fall in renal plasma flow (RPF) and glomerularKey words: leukotrienes, glomerular inflammation, dextran sieving,
transglomerular protein trafficking. filtration rate (GFR). Furthermore, an acute blockade
of LTD4 in models of nephrotoxic serum nephritis [10],Received for publication September 30, 1998
anti-Thy-1 antigen mesangiolysis [15], passive Heymannand in revised form January 29, 1999
Accepted for publication February 19, 1999 nephritis [16], and murine lupus nephritis [8] is associated
with an improvement in GFR and a reduction in protein- 1999 by the International Society of Nephrology
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uria. The key enzyme in the formation of LTs is the all instances. Five patients had lupus (SLE) nephritis (2
with the diffuse proliferative variety, 2 with the focal5-LO, in which the activity requires activation by a cell
membrane-bound protein called 5-LO activating protein proliferative variety, and 1 with membranous lupus ne-
phritis). Two patients had IgA nephropathy, and the(FLAP). In animals with experimental glomerulonephri-
tis, 5-LO inhibition or prevention of 5-LO-FLAP binding other four had membranoproliferative, membranous, id-
iopathic crescentic, and C1q deficiency associated glo-by “FLAP antagonists” results in marked reduction in
proteinuria and preservation of GFR [17, 18]. In humans, merulonephritis [1]. At the time of entry, the mean serum
creatinine (SCr) was 1.2 mg/dl (108 mm/liter), with a rangeevidence for the role of the 5-LO products in mediating
glomerulonephritis is supported by the finding of expres- of 0.5 (44 mm/liter) to 2.85 (251 mm/liter), and the median
proteinuria was 6253 mg/day (range 851 to 18,549 mg/sion of 5-LO and FLAP mRNAs in kidney biopsies of
patients with IgA nephropathy and mesangial prolifera- day). Four of the five SLE patients were receiving
chronic prednisone treatment at a dose of 10 to 30 mg/tive glomerulonephritis, but not in healthy controls [19].
Moreover, the expression of 5-LO and FLAP mRNA in day, and nine patients were on antihypertensive treat-
ment: converting enzyme inhibitors [5], diuretics [4], cal-glomerulonephritis patients correlated with the severity
of proteinuria and serum creatinine levels [19]. cium channel blockers [1], and b blockers [1]. The dose
of the chronic immunosuppressive and antihypertensiveRecently, 5-LO inhibitors have become available for
human use [20, 21], thus providing a tool to test the regimens was maintained unchanged during the duration
of the study.potential benefit of suppressing LT generation on the
course of human glomerulonephritis. MK-591 is a
Study design2-indolealkanoic acid derivative and chemically is 3-
(1-4[(4-chlorophenyl)methyl]-3-[(t-butylthio)-5-((2- The study was designed as a pilot, short-term, open-
label study. We obtained permission from the U.S. Foodquinoly)methoxy)-1H-indole-2]-a,a dimehtylpropanoic
acid (Fig. 1), which is an orally active 5-lipooxygenase and Drug Administration to conduct a pilot study of the
effects of MK-591 on glomerular function in patientsactivating protein antagonist [22]. MK-591 binds to
FLAP and thus inhibits the translocation and activation with glomerulonephritis. After obtaining informed con-
sent to a protocol approved by the Emory Universityof the 5-LO. MK-591 is rapidly absorbed and reaches Cmax
at approximately three hours. Absorption is significantly Human Investigations Committee, patients were admit-
ted to the General Clinical Research Center at Emoryreduced by food intake, and the drug should be given
on an empty stomach. The drug is metabolized by the University for renal function studies (discussed later in
this article). After baseline measurements, MK-591 wasliver with an elimination half-life (t1/2) of 13 hours [22].
MK-591 at doses of 50 to 500 mg inhibits ionophore- administered at a dose of 100 mg by mouth (p.o.) twice
a day for four days. This dose had previously been shownstimulated production of LTB4 in blood in a dose-depen-
dent manner from 1 hour until 12 to 48 hours after a to inhibit more than 85% LTD4 and E4 levels in plasma
and urine [23, 24]. Patients were readmitted at the endsingle-dose administration and reduces the urinary ex-
cretion of endogenous LTE4 by more than 80% from 8 of the study period again for renal function studies. All
other medications, including antihypertensives and main-hours until 48 to 72 hours after drug administration. The
side-effects are usually mild and transient (abdominal tenance prednisone, were continued at the same dosage
during the treatment phase. No dietary counseling wasdiscomfort and diarrhea) and occur more commonly at
high doses (500 mg). A skin rash that resolved with given during the study period. A complete blood count
(CBC) and serum chemistry panel (SMA-18) were ob-the discontinuation of the drug has been occasionally
observed [22–24]. tained prior to the initiation of MK-591, at the comple-
tion of treatment and one week thereafter. We definedThe purpose of our study was to characterize the ef-
fects of short-term inhibition of LT biosynthesis with an “response” as a reduction in the albumin and IgG excre-
tion rates, accompanied by a reduction in the fractionalorally active 5-lipoxygenase activating protein antagonist
(MK-591) on glomerular function in patients with glo- albumin and IgG clearances.
merulonephritis.
Glomerular function studies
A differential solute clearance technique was used to
METHODS
measure glomerular function as previously described
Patient population [26]. Briefly, two intravenous catheters were inserted,
one in each arm, to infuse clearance markers and collectWe enrolled 11 consecutive adult patients (4 males, 7
females, with a median age of 38 years and a range of blood. After a baseline blood sample, diuresis was initi-
ated with a 10 to 15 ml/kg water load and was maintained24 to 73) who had been referred to the Emory University
Renal Clinic because of a diagnosis of glomerulonephri- by drinking an equivalent volume of water to that of
voided urine. Intravenous loading doses of inulin, para-tis. The diagnosis was confirmed by a kidney biopsy in
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aminohippuric acid (PAH), and dextran 40 were admin-
istered, followed by an intravenous infusion to maintain
target constant levels [26]. Following a 40-minute equili-
bration period, four or five urine collections of 30-minute
durations were obtained by spontaneous voiding, with
blood samples taken at the beginning and end of each
urine collection. GFR was calculated as the average of
the four inulin clearances, and the RPF was calculated
as the average of the clearances of PAH, corrected for
tubular extraction. To account for the decrease in tubular
uptake of PAH that occurs in renal failure, we used an
Fig. 1. Structural formula of MK-591.extraction of PAH of 0.70 in patients with renal insuffi-
ciency (GFR , 80 ml/min/1.73 m2) and of 0.85 in patients
with a preserved GFR [27]. The filtration fraction was
calculated as the ratio between GFR and RPF. Fractional mally distributed and were log transformed prior to the
dextran clearances were calculated by dividing the clear-
statistical analysis to approximate a normal distribution.ance of each macromolecule by that of freely filtered
Pre- and post-MK-591 measurements were made by ainulin.
paired t-test using the Bonferroni correction for multipleThe concentrations of inulin and PAH were measured
comparisons. Results are considered significant when theas described in a previous study [28]. Plasma albumin and
P was less than 0.05.IgG concentrations were measured by a turbidometric
technique using specific antibodies, and in urine, by ra-
dioimmunoassay and enzyme-linked immunosorbent RESULTS
assay, respectively, as reported previously [28]. Dextran At baseline, proteinuria was markedly increased in all
in urine and plasma was separated by size-exclusion patients and averaged 3233 6 1074 and 194 6 78 mg/
chromatography, using precalibrated Sephacryl HR-300 min for albumin and IgG, respectively (Table 1). This
columns (Pharmacia, Uppsala, Sweden) and was mea- heavy proteinuria was accompanied by a reduction in
sured by the anthrone method [29]. The glomerular he- serum albumin (32 6 3 g/liter) and plasma oncotic pres-
modynamic and dextran sieving data were analyzed ac- sure (21 6 2 mm Hg). Despite a normal serum creatinine
cording to a heteroporous model (“isoporous 1 shunt”) on average (1.2 mg/dl, 108 mm/liter), GFR was reduced
of the glomerular capillary wall (GCW). This model
to approximately 60% of normal (62 6 9 ml/min/1.73allows the computation of the intrinsic filtering proper-
m2). The reduction in GFR was out of proportion to theties of the GCW, thus providing a tool to separate the
RPF, as indicated by a low filtration fraction (0.14 vs.effects on GFR caused by hemodynamic forces from
0.20 in healthy individuals) and was primarily mediatedthose caused by changes in ultrafiltration membrane
by a reduction in the two-kidney ultrafiltration coeffi-properties. According to this model [30], the GCW is
cient, Kf to 4 6 1 vs. 16 6 2 (ml/min · mm Hg21)/1.73perforated by two populations of pores in parallel: The
m2 in a group of 17 healthy individuals reported pre-main glomerular restrictive pores (ro). perforate the ma-
viously [29].jority of the membrane. In addition, a small portion of
The effect of treatment with MK-591 on protein excre-the membrane is occupied by large pores that do not
tion is shown in Figure 2. Treatment with MK-591 causeddiscriminate the passage of dextrans and behave as a
a significant reduction in proteinuria, both for albuminshunt pathway. The prominence of the shunt pathway
and IgG. The albumin excretion rate (AER) was de-is characterized by vo, which approximates the percent-
creased in 9 of the 11 patients, whereas in 2 (1 withage of filtrate volume permeating the shunt-like pores;
membranous lupus nephritis and 1 with idiopathic cres-the model also allows the estimation of the contribution
centic GN), the proteinuria was unchanged (Fig. 2). Theof the shunt to the fractional clearance of a macromole-
percentage reduction in albuminuria in the nine respond-cule (that is, a protein), as u∞ [30]. An additional com-
ers was 5 to 68%. It is worth noting that the two nonre-puted parameter is the two-kidney ultrafiltration coeffi-
sponders had a lower baseline AER (204 and 553 mg/cient or Kf. Because the mean arterial pressure was
min, respectively) versus a median value of 1960 mg/minunchanged during the study (Table 1) for all calculations,
(range 10,442 to 739) for the responders, suggesting thatwe assumed that the intraglomerular hydraulic pressure
patients with albuminuria of less than approximately 600(DP) was constant at 40 mm Hg [31].
mg/day may not respond to short-term therapy with MK-
Statistical analysis 591 with a detectable reduction in proteinuria. For all
patients combined, the average reduction in AER wasResults are expressed as mean 6 sem, unless indicated
otherwise. Values for protein excretion were not nor- 45%, from 3233 6 1074 to 1702 6 555 mg/min, pretreat-
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Table 1. Glomerular function and protein excretion
MAP
GFR RPF FF Serum albumin S. IgG AER IgGER
mm Hg ml/min/1.73m2 g/liter lg/min
Controls 8962 99 64 513622 0.2060.01 47 61 1361 5 61 1 61
Baseline 9964a 6269a 467679 0.1460.01a 3263a 1162 323361074a 194678a
Post-treatment 9865a 6269a 454668 0.1460.01a 3163a 1062 17026555ab 148655ab
Abbreviations are: MAP, mean arterial pressure; GFR, glomerular filtration rate; RPF, renal plasma flow; FF, filtration fraction; AER, albumin excretion rate;
IgGER, IgG excretion rate. Values for 17 controls had been reported previously [29].
a P , 0.05 vs. controls
b P , 0.05 post-treatment vs. baseline
Fig. 2. The effects of treatment with MK-591
on albumin excretion rate (A) and IgG excre-
tion rate (B) are shown. Mean values for pro-
tein excretion, pretreatment, and post-treat-
ment are indicated separately by a solid circle
with the vertical bar indicating the sem. *P ,
0.05.
ment and post-treatment, respectively (P , 0.05). The
corresponding values for IgG were 194 6 78 and 148 6
55 mg/min (P , 0.05). The ratio between the fractional
clearances of IgG and albumin or “selectivity index” was
unchanged with treatment (0.22 6 0.03 vs. 0.24 6 0.05,
before and after treatment, respectively, P 5 NS). Treat-
ment with MK-591 did not reduce GFR or RPF (Table
1), and the mean arterial pressure remained stable with
treatment. Because of the short duration of the treatment
(4 days), the reduction in proteinuria was not associated
with a significant change in serum protein concentrations
(Table 1).
The changes in dextran sieving caused by MK-591
therapy are shown in Figure 3. As compared with a group
of 17 healthy individuals reported previously [29], shown
as the dashed line in Figure 3, dextran-sieving behavior
in patients with glomerulonephritis was characterized by
enhanced passage of large dextrans (.52 A˚) and a rela-
tive restriction to the clearance of the smaller dextrans
(Fig. 3). Treatment with MK-591 was associated with a
Fig. 3. The fractional dextran clearances at baseline (j) and afterselective improvement in the abnormal passage of large
treatment with MK-591 (d) are shown. The dashed line (shown for
dextrans (.52 A˚), which achieved statistical significance comparison) indicates the fractional dextran clearance in 17 healthy
individuals reported previously. *P , 0.05.for dextrans .58 A˚ (P , 0.05). The fractional clearance
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Fig. 4. Effects of treatment with MK-591 on glomerular membrane parameters and proteinuria: (A) main glomerular pores (ro), (B) shunt parameter
(vo), (C) fractional protein clearance via shunt (u∞), (D) and the fractional clearances of albumin (s) and IgG (n). *P , 0.05 vs. pretreatment.
of smaller dextrans was unchanged, as compared with is directed at selectively blocking LT formation. Our
baseline. From the dextran sieving and the hemodynamic study shows that acute, short-term inhibition of LT bio-
determinations, we computed the glomerular membrane synthesis using an orally active FLAP antagonist causes
parameters, which are shown in Figure 4. Short-term a significant reduction in proteinuria and an improve-
therapy with MK-591 caused a selective improvement ment in GCW function. Moreover, the reduction in pro-
in the shunt parameter (vo), which was reduced from teinuria was not the result of a decrease in systemic blood
5.7 6 1.2 3 1023 to 3.6 6 0.8 3 1023 (P , 0.05), indicating pressure or a reduction in GFR, but resulted from an
an improvement in glomerular size selectivity. This im- improvement in capillary wall permeability. In addition,
provement in size selectivity was accompanied by a re- MK-591 was well tolerated, and no adverse effects were
duction in the fractional protein clearance attributable observed.
to the shunt (u∞) and the respective fractional protein The antiproteinuric action of MK-591 resulted from
clearances (albumin and IgG; Fig. 4C and 4D). The shunt a reduction in the transglomerular passage of macromol-
parameter also correlated with the fractional albumin ecules, as indicated by the improvement in the dextran
clearance (r 2 5 0.84, P , 0.05) and the fractional IgG sieving curve. MK-591 caused a reduction in the abnor-
clearance (r 2 5 0.86, P , 0.05). The size of the main mal passage of large dextrans (Fig. 3) and of the com-
glomerular pores (ro; Fig. 4A) and the two-kidney ultra- puted shunt parameter, vo (Fig. 4). Neither the size
filtration coefficient were unchanged (data not shown). of the main restrictive pores (ro) nor the ultrafiltration
coefficient was altered. This indicates that MK-591 ther-
Adverse experiences and proteinuria follow-up apy improves glomerular size selectivity. By measuring
MK-591 was well tolerated in all patients, and no ad- the excretion rates of two plasma proteins—albumin, a
verse clinical or biochemical (CBC and SMA-18) se- relatively small anionic protein, and IgG, a large, neutral
quelae were reported or observed. Specifically, no pa- protein (Table 1)—we indirectly estimated the effects of
tient developed gastrointestinal side effects or skin MK-591 on charge selectivity. The ratio between the
rashes. We measured proteinuria again one week after fractional clearances of IgG and albumin is known as the
discontinuation of MK-591. The two patients with diffuse “selectivity index.” When analyzed along with dextran
proliferative lupus nephritis had been given intravenous sieving, this index provides an indirect assessment of the
cyclophosphamide after the completion of MK-591 treat- contribution of a charge-selective defect to proteinuria.
ment and were excluded from the analysis. Proteinuria, The “selectivity index” was unchanged with treatment
expressed as milligrams of protein per milligram of creat- (0.22 6 0.03 vs. 0.24 6 0.05, before and after treatment,
inine, was unchanged after one week washout (4.5 6 1.7
respectively, P 5 NS). This suggests that antagonism ofvs. 4.2 6 1.6, respectively), suggesting that the antipro-
FLAP does not result in the acute reversal of a mem-teinuric effect of MK-591 persisted for one week after
brane charge-selectivity defect. Rather, these studiesdrug discontinuation.
strongly suggest that MK-591 directly improves glomeru-
lar barrier function and porosity, and thus decreases
DISCUSSION proteinuria.
In experimental models of early immune-mediatedThis is the first human study, to our knowledge, in
which the treatment of patients with glomerulonephritis glomerular injury, a blockade of LT synthesis results in
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generous support of Gambro Healthcare to the Center for Glomerulo-a reduction of proteinuria, lowering of intraglomerular
nephritis of Emory University. MK-591 was a gift from Merck & Co.,pressure resulting from efferent arteriolar vasodilation, Inc. (Whitehouse Station, NJ, USA). This was presented in part at the
and a restoration of GFR and the ultrafiltration coeffi- 29th annual meeting of the American Society of Nephrology, New
Orleans, Louisiana, in November 1996.cient (Kf) [10]. In contrast to the experimental models
in rodents, the reduction of proteinuria in our patients Reprint requests to Kamal F. Badr, M.D. or Antonio Guasch, M.D.,
with glomerulonephritis was not associated with an acute Renal Division, Emory University, 1840 Southern Lane, Decatur, Geor-
gia 30033, USA.improvement in GFR. We cannot, however, exclude a
“silent” improvement in the glomerular Kf in MK-591–
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